PDCD1 and non-small cell lung carcinoma: A recent paper using data from 37 advanced NSCLC patients receiving nivolumab enrolled in the study from the clinical trials CheckMate 078 (NCT02613507) and CheckMate 870 (NCT03195491) demonstrated a strong correlation between the level of gut microbiome diversity and anti-PD-1 efficacy in advanced NSCLC Chinese patients.